PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'The George Institute for Global Health, University of New South Wales, Sydney, Australia.\', \'The George Institute for Global Health, Imperial College London, London, UK.\', \'Prince of Wales Hospital, Sydney, Australia.\', \'The George Institute for Global Health, University of New South Wales, Sydney, Australia. arlen.wilcox@sydney.edu.au.\', \'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. arlen.wilcox@sydney.edu.au.\', \'The George Institute for Global Health, New Delhi, India.\', \'Queensland University of Technology, Brisbane, Australia.\', \'Royal North Shore Hospital, Sydney, Australia.\', \'Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.\', \'Department of Medicine, The University of Melbourne, Austin Health, Heidelburg, Victoria, Australia.\', \'All India Institute of Medical Sciences, Raipur, India.\', \'Christian Medical College, Ludhiana, India.\', \'Concord Repatriation General Hospital, Sydney, Australia.\', \'The University of Sydney, Sydney, Australia.\', \'Sydney School of Public Health, University of Sydney, Sydney, Australia.\', \'The Sydney Children\'s Hospitals Network, Westmead, NSW, Australia.\', \'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1186/s13063-021-05521-0
?:doi
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 34454580
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
?:title
  • Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all